Clearmind Medicine completed the last treatment of its first cohort in a Phase I/IIa trial for CMND‑100, an oral MEAI‑based therapy for alcohol use disorder.
Six patients were enrolled and dosed—two at Johns Hopkins University School of Medicine and four at Yale School of Medicine’s Department of Psychiatry—while two additional sites in Israel were activated for the study.
The single‑ and multiple‑dose study, conducted under an FDA Investigational New Drug approval, evaluated safety, tolerability, and pharmacokinetics and explored preliminary efficacy signals such as reductions in alcohol cravings and consumption.
The company’s financial statements show a negative EBITDA of $5.79 million for the most recent twelve months, a cash burn rate that limits the current runway, and a need for additional capital to fund ongoing development.
Clearmind has secured up to $10 million in convertible notes to support the next phases of the program and to maintain clinical and regulatory momentum.
Industry analysts project the global alcohol‑dependency treatment market to reach approximately $20 billion by 2032, a figure that reflects the growing demand for effective outpatient therapies.
Competitive peers include Alkermes, which markets Vivitrol, and Adial Pharmaceuticals, which is developing AD04; Clearmind’s oral approach offers a distinct modality that could complement existing treatment options.
The trial’s successful completion of the first cohort provides critical safety data and positions CMND‑100 for subsequent cohorts and eventual Phase IIb/III development, advancing the company’s strategic objective of delivering a new treatment option for patients with alcohol use disorder.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.